glp 1 being discontinued Are Compounded GLP-1s Going Away? Not Entirely GLP-1 agonist Victoza to be

Georgiev V.G., Weber J., Kneschke E.M., Denev P.N., Bley T., Pavlov A.I

The formal pharmacokinetic data showing a 33% increase in levothyroxine exposure was studied with oral semaglutide specifically, but injectable formulations of both drugs also slow gastric emptying enough to affect thyroid medication absorption

However, in November 2021, approval was withdrawn after the marketing authorisation holder withdrew the indication for type 1 diabetes across Europe and the UK

2020;7:CD012990

The most common adverse effectsnausea, vomiting, abdominal pain, and diarrheaare often triggered or worsened by large portions and high-fat meals typical of restaurant dining